Reaction
Cystitis Noninfective reporting signals
As of the last recalculation, Cystitis Noninfective appears in 1,323 FAERS reports alongside 35 co-occurring drug terms. The strongest observed disproportionality signal is OCRELIZUMAB (PRR 62.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ocrelizumab | 208 | 62.4 | 62.6 |
| Nevirapine | 24 | 42.6 | 42.7 |
| Efavirenz | 25 | 35.9 | 36.0 |
| Zidovudine | 26 | 31.2 | 31.2 |
| Atazanavir | 25 | 27.9 | 27.9 |
| Chlorhexidine Gluconate | 16 | 27.9 | 27.9 |
| Ritonavir 100 Mg | 25 | 26.8 | 26.9 |
| Darunavir | 25 | 26.5 | 26.5 |
| Raltegravir | 25 | 24.3 | 24.3 |
| Trimethoprim | 15 | 20.2 | 20.3 |
| Pertuzumab | 34 | 20.2 | 20.2 |
| Vincristine Sulfate | 32 | 17.6 | 17.6 |
| Lopinavir And Ritonavir | 14 | 16.4 | 16.4 |
| Doxepin | 10 | 15.6 | 15.6 |
| Nitrofurantoin | 15 | 14.5 | 14.5 |
| Nitrofurantoin (Monohydrate/Macrocrystals) | 15 | 14.3 | 14.3 |
| Doxepin Hydrochloride | 11 | 13.8 | 13.8 |
| Ritonavir | 25 | 13.7 | 13.7 |
| Desloratadine | 8 | 11.8 | 11.8 |
| Baricitinib | 7 | 11.5 | 11.5 |
| Doxorubicin Hydrochloride | 23 | 11.3 | 11.3 |
| Baclofen | 53 | 10.0 | 10.1 |
| Dalfampridine | 43 | 9.7 | 9.7 |
| Triamcinolone Acetonide Ointment Usp, 0.05% | 14 | 9.5 | 9.5 |
| Levodopa | 7 | 9.2 | 9.2 |
| Mirabegron | 20 | 8.2 | 8.2 |
| Trastuzumab | 33 | 7.7 | 7.7 |
| Fesoterodine Fumarate | 5 | 7.3 | 7.3 |
| Rotigotine | 6 | 6.6 | 6.6 |
| Irinotecan Hydrochloride | 5 | 6.1 | 6.1 |
| Docetaxel Anhydrous | 25 | 5.9 | 5.9 |
| Docetaxel | 25 | 5.9 | 5.9 |
| Botulinum Toxin Type A | 4 | 5.1 | 5.1 |
| Onabotulinumtoxina | 24 | 5.0 | 5.0 |
| Atezolizumab | 10 | 4.1 | 4.1 |